E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chemotherapy induced peripheral neuropathy |
|
E.1.1.1 | Medical condition in easily understood language |
Damages to nerves of the peripheral nervous system, induced by chemotherapy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10079545 |
E.1.2 | Term | Chemotherapy induced peripheral neuropathy |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare PledOx (5 µmol/kg) vs placebo with respect to the proportion of patients with moderate or severe chronic CIPN |
|
E.2.2 | Secondary objectives of the trial |
To compare PledOx vs placebo:
Efficacy
• The proportion of patients with mild, moderate or severe chronic CIPN
• The sensitivity to touching cold items
• The cumulative dose of oxaliplatin during chemotherapy
• The vibration sensitivity on the lateral malleolus
• The worst pain in hands or feet
• The functional impairment (in the non-dominant hand)
• The sustained efficacy on prevention of CIPN during long-term follow-up
Safety
• DFS
• Safety and tolerability
Exploratory
• Chronic CIPN by supporting analysis using the full FACT/GOG NTX-13
• The cumulative dose of 5-FU during chemotherapy
• For both oxaliplatin and 5-FU: Dose intensity, number of cycles, dose reductions, reason(s) for dose reductions, patients with dose delays, and length of dose delays
• Quality of Life/health status
• The functional impairment (in the non-dominant hand) during long-term follow-up
• The worst pain in hands or feet during long-term follow-up.
• Health economic impact |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent form before any study related assessments and willing to follow all study procedures.
2. Male or female aged ≥18 years.
3. Pathologically confirmed adenocarcinoma of the colon or rectum including: Stage III carcinoma (any T N1,2 M0) or Stage II carcinoma (T3,4 N0 M0).
4. The patient has undergone curative (R0) surgical resection performed not less than 28 days and generally not more than 8-12 weeks prior to randomization.
5. The patient has a postsurgical CEA level ≤1.5 x upper limit of normal (ULN, in current smokers, CEA level ≤2.0 x ULN is allowed).
6. No prior anti-cancer therapy for CRC except radiotherapy or concomitant chemoradiotherapy using a fluoropyrimidine alone for locoregional rectal cancer.
7. Patient indicated for up to 6 months of oxaliplatin-based chemotherapy and without any clinically observed neurological disorders.
8. ECOG performance status of 0 or 1.
9. Adequate hematological parameters: hemoglobin ≥100 g/L, absolute neutrophil count (ANC) ≥1.5 x 109 /L, platelets ≥100 x 109 /L.
10. Adequate renal function: creatinine clearance >50 cc/min using the Cockroft and Gault formula or measured.
11. Adequate hepatic function: total bilirubin ≤1.5 x ULN (except in the case of known
Gilbert’s syndrome); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x ULN (AST and ALT ≤5 x ULN in case of liver metastases).
12. Baseline blood Mn level <2.0 x ULN.
13. For patients with a history of diabetes mellitus, HbA1c ≤7%.
14. Negative pregnancy test for females of child-bearing potential.
15. For men and females of childbearing potential, use of adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) while on study drug and for at least 6 months after completion of study therapy. |
|
E.4 | Principal exclusion criteria |
1. Any evidence of metastatic disease.
2. Any unresolved toxicity by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v.4.03) >Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia.
3. Any grade of neuropathy from any cause.
4. Any prior oxaliplatin-based chemotherapy <1 year before the randomization.
5. Any evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac, unresolved bowel obstruction, hepatic or renal disease).
6. Chronic infection or uncontrolled serious illness causing immunodeficiency.
7. Recent (<28 days) surgery prior to entry into the study or a surgical incision that is not fully healed.
8. Known hypersensitivity to any of the components of mFOLFOX6 and, if applicable, therapies to be used in conjunction with the chemotherapy regimen or any of the excipients of these products.
9. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for that other malignancy for at least 2 years.
10. Known dihydropyrimidine dehydrogenase deficiency.
11. Pre-existing neurodegenerative disease (e.g., Parkinson’s, Alzheimer’s, Huntington’s) or neuromuscular disorder (e.g., multiple sclerosis, amyotrophic lateral sclerosis, polio, hereditary neuromuscular disease).
12. Major psychiatric disorder (major depression, psychosis), alcohol and/or drug abuse.
13. Patients with a history of second or third degree atrioventricular block or a family heredity.
14. A history of a genetic or familial neuropathy.
15. Treatment with any investigational drug within 30 days prior to randomization.
16. Pregnancy, lactation or reluctance to using contraception.
17. Any other condition that, in the opinion of the Investigator, places the patient at undue risk.
18. Previous exposure to mangafodipir or calmangafodipir.
19. Welders, mine workers or other workers in occupations (current or past) where high Mn exposure is likely. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients scoring 3 or 4, derived as the maximum score of items NTX 1 to 4, in any of the symptoms of numbness, tingling and discomfort in hands and feet in the FACT/GOG-NTX-13, 9 months after the first dose.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
9 months after first dose of IMP |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints
Efficacy
• Proportion of patients (with mild, moderate or severe chronic CIPN) scoring 2, 3, or 4, in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of IMP
• Mean change from baseline in sensitivity to touching cold items on Day 2, Cycle 4 of mFOLFOX6 chemotherapy, as assessed by the Cold Sensitivity questionnaire
• Mean cumulative dose of oxaliplatin administered per patient during mFOLFOX6 chemotherapy, 9 months after the first dose of IMP
• Mean change from baseline in vibration sense, on the lateral malleolus (left and right), using a graduated tuning fork, at 9 months after the first dose of IMP
• Mean change from baseline in worst pain in hands or feet in the past week, using a numerical rating scale (NRS), at 9 months after the first dose of IMP
• Mean change from baseline in the time to complete the grooved Pegboard with the non-dominant hand, at 9 months after the first dose of IMP
• Proportion of patients scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 12, 18, and 24 months after the first dose of IMP
Safety
• DFS
• Safety and tolerability as assessed by adverse events (AEs), laboratory variables and vital signs
Exploratory Endpoints
• Frequency and proportion of patients with any CIPN scoring 1, 2, 3 or 4, in any of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, at all other timepoints after the first dose of IMP
• Mean score of the first 4 items of the FACT/GOG-NTX-13 (i.e. FACT/GOG-NTX-4), at 9 months after the first dose of IMP
• Mean score of the 13 items of the FACT/GOG-NTX-13, at 9 months after the first dose of IMP
• Mean cumulative dose of 5-FU administered per patient during mFOLFOX6 chemotherapy, 9 months after the first dose of IMP
• For both oxaliplatin and 5-FU: Dose intensity, mean number of cycles per patient, proportion of patients with any dose reduction, reason(s) for dose reductions, proportion of patients with any dose delay, and mean duration of dose delay
• Mean health index and mean visual analogue scale (VAS) score, using the EQ-5D-5L, at 9, 12, 18, and 24 months after the first dose of IMP
• Mean health index, using the FACT/GOG, at 9, 12, 18, and 24 months after the first dose of IMP
• Mean time to complete the grooved Pegboard, with the non dominant hand, at 12, 18, and 24 months after the first dose of IMP
• Mean change from baseline in worst pain in hands or feet in the past week, using a NRS, at 12, 18, and 24 months after the first dose of IMP
• The proportion of patients with a 2-point, 3-point and 4-point increase in worst pain in hands or feet in the past week, using a NRS, at 9, 12, 18, and 24 months after the first dose of IMP
• Health economic impact, measured by the combined impact of medical resource utilization (hospitalizations, outpatient visits, medical procedures and medical use), patient impact (AEs, fall accidents, functional loss) and indirect societal costs (loss of ability to work), up to 24 months after the first dose of IMP |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- FACT/GOG-NTX-13, Grooved pegboard, Grad. Tuning fork, Pain NRS: treatment visits 1-12 (D1 of each Cyc), assessment visits M3, 6, 9, 12, 18 & 24, EoT (D14 last cycle)
- AEs: treatment V1-12, EoT
- DFS : assessment M3, 6, 9, 12, 18 & 24, EoS
- Biochem & Blood Mn: Screen, treatment V1, 4, 8, 12, EoT
- Hemato: Screen, treatment V1-12, EoT
- Vital sign, ECOG: Screen, treatment V1-12, M3, 6, 9, 12, 18 & 24, EoT
- Cold sensitivity: Screen, treatment V2, 4 & 8
- QoL/health status: treatment V1, 4, 8 & 12, M6-24
- Physical exam: Screen, assesment M3-24, EoT
- MRI of CNS and Blood Mn incl. neuro exam: treatment visits 1-12, M3, EoT
- ECG: Screen
- Health eco: treament V1, EoT, M12 & M24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 56 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |